Bellon Christine 4

What Happened Christine Bellon, Chief Legal Officer of Beam Therapeutics (BEAM), sold 5,956 shares of common stock in an open-market transaction on April 1, 2026 at $24.58 per share, resulting in gross proceeds of $146,398. This was a sale (not a purchase) and was completed to cover tax withholding obligations tied to vested restricted stock units.

Key Details

• Transaction date and price: April 1, 2026 — 5,956 shares sold at $24.58/share (gross proceeds $146,398).
• Transaction type: Sale (open market/private sale reported as "S").
• Shares owned after transaction: Not specified in the filing.
• Footnote: The shares were automatically sold to cover tax withholding upon vesting of RSUs granted on March 31 of 2022, 2023, 2024 and 2025; sales were effected pursuant to a Rule 10b5-1 trading plan adopted May 19, 2023 (see footnote F1).
• Filing: Form filed April 6, 2026 for a April 1 transaction — Form 4s are normally due within two business days, so this filing occurred several days after the trade.

Context Sales that occur automatically to satisfy tax-withholding on vested RSUs and that are executed under a pre-established 10b5-1 plan are generally considered routine and do not necessarily signal a change in the insider’s view of the company. This report documents a tax-withholding sale rather than a discretionary divestiture.